Tissuetech

BioTissue is the leader in innovative technologies using products derived from human amniotic membrane tissues. In 1997, BioTissue was the first company to introduce the use of cryopreserved amniotic membrane tissue for clinical application, by utilizing its proprietary CryoTek technology, proven to preserve the innate biological and structural properties of the amniotic membrane tissue. By adopting the BioTissue name across the entire organization, the company will also reflect that innovative heritage and promise in its surgical business, which was previously known as Amniox Medical. BioTissue is pursuing FDA approval through submission of a Biologics License Applications (BLA) for some of our products as evidenced in a recently published Phase 2 study for complex diabetic foot ulcers.20 Our company will continue to provide sustainable health economic value, solve unmet clinical needs, and lead in technological innovation in seeking to deliver the promise of regenerative healing for our physicians and patients. Our extensive research allows us to preserve and deliver the most functional allograft for your needs. We empower healthcare professionals to deliver optimal patient healing outcomes, setting the standards that define next-generation care. TissueTech was founded in 2001 as the parent entity for BioTissue Inc., which develops and markets regenerative therapies for treating the ocular surface. In 2011, our company expanded from ocular space and its product offerings that, include Prokera®, AmnioGraft® and AmnioGuard® to additional market segments such as orthopedics,14-16 neuropathy,17 wound care,18-23 spine,24 urology25, and pain management26,27 using the same birth tissue products processed using our patented manufacturing technology.